Compounds > fludarabine

fludarabine and Genetic Predisposition

fludarabine has been researched along with Genetic Predisposition in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Melarcode Ramanan, K; Patel, S; Raj, R; Ravichandran, N; Uppuluri, R; Vellaichamy Swaminathan, V1
Treon, SP1
Burgaleta, C; Cabrera, C; Canales, M; De la Serna, J; Fernández de Sevilla, A; Gonzalez, M; Martínez, R; Martínez-López, J; Montalbán, C; Monteagudo, MD; Paz-Carreira, J; Peñalver, FJ; Peñarrubia, MJ; Prieto, E; Queizán, JA; Rapado, I; Rivero, A; Salar, A; Sánchez-Godoy, P; Tomás, JF1
Bühler, A; Busch, R; Denzel, T; Döhner, H; Groner, S; Häbe, S; Hallek, M; Mertens, D; Mohr, J; Sarno, A; Stilgenbauer, S; Winkler, D; Zenz, T1
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B1
Bentley, P; Fegan, C; Hooper, L; Hoy, T; Milligan, D; Pepper, C; Pratt, G; Starczynski, J; Thomas, A1
Byrd, JC; Caligiuri, MA; Grever, MR; Gribben, JG; Heerema, NA; Lampson, B; Larson, RA; Lozanski, G; Lucas, DM; Peterson, BL1
Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G1

Trials

1 trial(s) available for fludarabine and Genetic Predisposition

ArticleYear
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Blood, 2009, Sep-24, Volume: 114, Issue:13

    Topics: Administration, Cutaneous; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p21; DNA Mutational Analysis; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Signal Transduction; Treatment Failure; Tumor Suppressor Protein p53; Vidarabine

2009

Other Studies

7 other study(ies) available for fludarabine and Genetic Predisposition

ArticleYear
Mendelian susceptibility to mycobacterial disease-Challenges in hematopoietic stem cell transplantation.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:5

    Topics: Allografts; Child, Preschool; Dexamethasone; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Mutation; Mycobacterium; Mycobacterium Infections; Receptors, Interleukin-12; Transplantation Conditioning; Vidarabine

2020
How I treat Waldenström macroglobulinemia.
    Blood, 2015, Aug-06, Volume: 126, Issue:6

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia

2015
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:8

    Topics: Adult; Aged; Alleles; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Early Termination of Clinical Trials; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Haplotypes; Humans; Infections; Lymphoma, Follicular; Lymphopenia; Male; Mannose-Binding Lectin; Middle Aged; Multicenter Studies as Topic; Neutropenia; Prospective Studies; Risk; Rituximab; Spain; Vidarabine; Young Adult

2009
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2012
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
    British journal of haematology, 2003, Volume: 123, Issue:1

    Topics: Aged; Antineoplastic Agents; Case-Control Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Frequency; Genes, bcl-2; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Vidarabine

2003
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Female; Gene Deletion; Genes, Immunoglobulin Heavy Chain; Genetic Predisposition to Disease; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rituximab; Tumor Suppressor Protein p53; Vidarabine

2006
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2000